<DOC>
	<DOCNO>NCT00255801</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin bexarotene , work different way stop growth cancer cell , either kill cell stop dividing . Bexarotene may also cause cutaneous T-cell lymphoma cell look like normal cell , grow spread slowly . Giving liposomal doxorubicin follow bexarotene may effective treatment cutaneous T-cell lymphoma . PURPOSE : This phase II trial study well give liposomal doxorubicin follow bexarotene work treat patient cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Liposomal Doxorubicin Followed By Bexarotene Treating Patients With Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient stage IB-IV cutaneous T-cell lymphoma treat doxorubicin HCl liposome follow bexarotene . Secondary - Determine complete partial response rate patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive doxorubicin HCl liposome IV 30-90 minute day 1 . Treatment repeat every 2 week 8 course . Beginning within 4 week last dose doxorubicin HCl liposome , patient receive oral bexarotene daily least 16 week . Patients achieve complete partial response may continue receive bexarotene absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous Tcell lymphoma Stage IBIV disease Measurable disease Newly diagnose previously treat disease No demonstrate resistance prior bexarotene PATIENT CHARACTERISTICS : Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular Ejection fraction ≥ 50 % MUGA 2D echocardiogram No New York Heart Association class IIIV heart disease No clinical evidence congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week completion study treatment No history hypersensitivity reaction attribute doxorubicin HCl liposome component No active potentially lifethreatening infection No acute disease PRIOR CONCURRENT THERAPY : Chemotherapy See Disease Characteristics Prior doxorubicin allow provided cumulative dose ≤ 300 mg/m^2 Prior epirubicin hydrochloride allow provided cumulative dose ≤ 540 mg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>